Jack Spruth

Breakthroughs in frontier science rarely come from a sudden stroke of luck. Every major leap in AI drug design is the product of years of method development, rigorous engineering, and learning from what came before. Witnessing the rapid advances in deep reinforcement learning and frontier AI capabilities led to a deep conviction: we could apply these same computational principles to other complex fields, like the engineering of new medicines. That thinking led to the formation of Isomorphic Labs in 2021. Now, five years on, we have compelling evidence that our AI can unlock therapeutics to a wide range of disease classes. We are confident this technology will fundamentally impact how new medicines are created, from early discovery all the way through development. In this article, I share the massive opportunity we have to transform human health with AI, and offer a look at the real, measurable progress we’re already making today. isomorphiclabs.com/articles/…